Implementation of prophylactic HPV vaccination: Progress and future challenges

Expert Review of Obstetrics and Gynecology

Volumn 5, Issue 5, 2010, Pages 591-603

  Brabin, Loretta ^a   Kitchener, Henry C ^a   Stern, Peter L ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

adolescent girls; cervical cancer; HPV vaccine programs; HPV vaccine uptake; human papillomavirus vaccine; males; older women

Indexed keywords

WART VIRUS VACCINE;

CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; PAPILLOMAVIRUS INFECTION; REVIEW; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

EID: 77956524029     PISSN: 17474108     EISSN: None     Source Type: Journal    
DOI: 10.1586/eog.10.42     Document Type: Review

References (124)

1. Franco EL, Coutlée F, Ferenczy A. Integrating human papillomavirus vaccination in cervical cancer control programmes. Pub. Health Genomics 12, 352-361 (2009).
2. Cuzick J, Castañón A, Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br. J. Cancer 102, 933-939 (2010).
3. Stanley M, Lowy DR, Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine 24, 106-113 (2006).
4. Stern PL, Kitchener HC. Vaccines for the Prevention of Cervical Cancer. Oxford University Press, Oxford, UK (2009).
5. Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, Shah KV. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin. Diagn. Lab. Immunol. 4, 122-126 (1997).
6. Viscidi RP, Schiffman M, Hildesheim A et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol. Biomarkers Prev. 13, 324-327 (2004).
7. Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. Virology 77, 13125-13135 (2003).
8. Richards RM, Lowy DR, Schiller JT, Day PM. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl Acad. Sci. USA 103, 1522-1527 (2006).
9. Roberts JN, Buck CB, Thompson CD et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 13, 857-861 (2007).
10. Conway MJ, Meyers C. Replication and assembly of human papillomaviruses. J. Dent. Res. 88, 307-317 (2009).
11. ® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccin. 5, 705-719 (2009).
12. Prakash M, Patterson S, Kapembwa MS. Macrophages are increased in cervical epithelium of women with cervicitis. Sex. Transm. Infect. 77, 366-369 (2001).
13. Muñoz N, Bosch FX, Castellsagué X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111, 278-285 (2004).
14. Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95, 1459-1466 (2006).
15. Olsson SE, Villa LL, Costa RL et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25, 4931-4939 (2007).
16. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356, 1915-1927 (2007).
17. FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369, 1861-1868 (2007).
18. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367, 1247-1255 (2006).
19. Schwarz TF. Human papillomavirus-16/18 candidate vaccine adjuvanted with AS04 and its impact on the incidence of cervical cancer. Expert Rev. Obstet. Gynecol. 2, 293-303 (2007).
20. The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374, 1975-1985 (2009).
21. Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet 369, 2161-2170 (2007).
22. David MP, Van Herck K, Hardt K et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol. Oncol. 115(3 Suppl.), S1-S6 (2009).
23. Reisinger KS, Block SL, Lazcano-Ponce E et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6,11,16,18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr. Infect. Dis. J. 26, 201-209 (2007).
24. Pedersen C, Petaja T, Strauss G et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J. Adolesc. Health 40, 564-571 (2007).
25. Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 26, 6529-6541 (2008).
26. Schwarz TF, Spaczynski M, Schneider A et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 27 581-587 (2009).
27. Munoz N, Manalastas R Jr, Pitisuttihum P et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women ages 24-45 years: a randomised, double-blind trial. Lancet 373, 1949-1957 (2009).
28. Grainge MJ, Seth R, Guo L et al. Cervical human papillomavirus screening among older women. Emerg. Infect. Dis. 11, 1680-1685 (2005).
29. Olsson SE, Kjaer SK, Sigurdsson K et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum. Vaccin. 5(10), 696-704 (2009).
30. Bosch FX, Burchell AN, Schiffman M et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 265, K1-K16 (2008).
31. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J. Infect. Dis. 200, 166-171 (2009).
32. Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J. Virol. 81, 8784-8792 (2007).
33. Paavonen J, Naud P, Salmerón J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374, 301-314 (2009).
34. Brown DR, Kjaer S, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199, 926-935 (2009).
35. Wheeler, CM, Kjaer SK, Sigurdsson K et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J. Infect. Dis. 199, 936-944 (2009).
36. Harper DN. Current prophylactic HPV vaccines and gynecologic premalignancies. Curr. Opin. Obstet. Gynecol. 21(6), 457-464 (2009).
37. Descamps D, Hardt K, Spiessens B et al. Safety of human papillomavirus (HPV)- 16/18 ASO4-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum. Vaccine 5, 332-340 (2009).
38. Wacholder S, Chen BE, Wilcox A et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomized controlled trials. Br. Med. J. 340, c712 (2010).
39. Dana A, Buchanan KM, Goss MA et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet. Gynecol. 114, 1170-1178 (2009).
40. Brabin L, Roberts SA, Stretch R et al. A survey of adolescent experiences of human papillomavirus vaccination in the Manchester study. Br. J. Cancer 101, 1502-1504 (2009).
41. Reid M. Report of an attitudinal study to inform Year 2 of the HPV immunisation programme in Scotland. NHS Health Scotland, Edinburgh, Scotland (2009).
42. Lenselink CH, Gerrits MMJG, Melchers WJG, Massuger LFAG, Van Hamont D, Bekkers RLM. Parental acceptance of human papillomavirus vaccine. Eur. J. Obstet. Gynecol. 137, 103-107 (2008).
43. Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am. J. Epidemiol. 171, 357-367 (2010).
44. Lévy-Bruhl D, Bousquet V, King LA et al. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey. Eur. J. Cancer 45, 2709-2713 (2009).
45. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med. 359, 821-822 (2008).
46. Zechmeister I, Freiesleben de Blasio B, Garnett G. HPV-vaccination for the prevention of cervical cancer in Austria: a model based long-term prognosis of cancer epidemiology. J. Pub. Health 18, 3-13 (2010).
47. CDC. National, state and local area vaccination coverage among adolescents aged 13-17 years - United States, 2008. MMWR Morb. Mortal. Wkly Rep. 58, 997-1001 (2009).
48. Markowitz LE, Hariri S, Unger ER, Saraiya M, Deblina Datta S, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 28(30), 4731-4737 (2010).
49. Simoens C, Sabbe M, Van Damme P, Beutels P, Arbyn M. Introduction of human papillomavirus (HPV) vaccination in Belgium, 2007-2008. Eurosurveillance 14, 1-4 (2009).
50. Jit M, Vyse A, Borrow R, Pebody R, Soldan K, Miller E. Prevalence of human papillomavirus antibodies in young female subjects in England. Br. J. Cancer 97, 989-991 (2007).
51. Roberts SA, Brabin L, Stretch R et al. Human papillomavirus vaccination and social inequality: results from a prospective cohort study. Epidemiol. Infect. DOI: 10.1017/S095026881000066X (2010) (Epub ahead of print).
52. Mixer RE, Jamrozik K, Newsom D. Ethnicity as a correlate of the uptake of the first dose of mumps, measles and rubella vaccine. J. Epidemiol. Comm. Health 61, 797-801 (2007).
53. Hilton S, Hunt K, Langan M, Bedford H, Petticrew M. Newsprint media representations of the introduction of the HPV vaccination programme for cervical cancer prevention in the UK (2005-2008). Soc. Sci. Med. 70, 942-950 (2010).
54. Mortenson GL. Drivers and barriers to acceptance of human-papillomavirus vaccination among young women: a qualitative and quantitative study. BMC Pub. Health 10, 68 (2010).
55. Rondy M, Van Lier A, Van de Kassteele J, Rust L, De Melker H. Determinants for HPV vaccine uptake in the Netherlands: a multilevel study. Vaccine 28, 2070-2075 (2010).
56. Brotherton JML, Mullins R. Estimating coverage of the National HPV Vaccination Program: where are we at? Med. J. Aust. 19, 188 (2009).
57. Watson M, Shaw D, Molchanoff L, McInnes C. Challenges, lessons learned and results following the implementation of a human papillomavirus school vaccination program in South Australia. Aust. N. Z. J. Pub. Health 33, 365-370 (2009).
58. Weisberg E, Bateson D, McCaffery K, Skinner S. HPV vaccination catch up program. Utilisation by young Australian women. Aust. Fam. Phys. 38, 72-76 (2009).
59. Ogilvie G, Anderson M, Marra F et al. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med. 7, e1000270 (2010).
60. Brabin L, Roberts RA, Farzaneh F, Kitchener HC. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine 24, 3087-3094 (2006).
61. Marlow LA, Waller J, Wardle J. Parental attitudes to pre-pubertal HPV vaccination. Vaccine 25, 1945-1952 (2007).
62. Pruitt SL, Schootman M. Geographic disparity, area poverty, and human papillomavirus vaccination. Am. J. Prev. Med. 38, 525-533 (2010).
63. Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J. Adolesc. Health 45, 453-462 (2009).
64. Reiter PL, Brewer NT, Gottlieb SL, McRee A-L, Smith JS. Parents health beliefs and HPV vaccination of their adolescent daughters. Soc. Sci. Med. 69, 475-480 (2009).
65. Bach PB. Gardasil: from bench, to bedside, to blunder. Lancet 375, 593-594 (2010).
66. Szilagyi P, Vann J, Bordley C et al. Interventions aimed at improving immunization rates. Cochrane Database Syst. Rev. 4, CD003941 (2002).
67. Fang CY, Coups EJ, Heckman CJ. Behavioral correlated of HPV vaccine acceptability in the 2007 Health Information National Trends Survey (HINTS). Cancer Epidemiol. Biomarkers Prev. 19, 319-326 (2010).
68. Schnatz PF, Humphrey K, OSullivan DM. Assessment of the perceptions and administration of the human papillomavirus vaccine. J. Low. Gen. Tract Dis. 14, 103-107 (2010).
69. Stretch R, McCann R, Roberts SA, Elton P. Baxter D, Brabin L. A qualitative study to assess school nurses views on vaccinating 12-13 year old school girls against human papillomavirus without parental consent. BMC Pub. Health 9, 254 (2009).
70. Mehu-Parant F, Rouzier R, Soulat J-M, Parant O. Eligibility and willingness of first-year students entering university to participate in a HPV vaccination catch-up program. Eur. J. Obstet. Gynecol. Rep. Biol. 148, 186-190 (2010).
71. Forster AS, Marlow LAV, Wardle J, Stephenson J, Waller J. Understanding adolescents intentions to have the HPV vaccine. Vaccine 28, 1673-1676 (2010).
72. Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet. Gynecol. 111, 1103-1110 (2008).
73. Allen JD, Mohllajee AP, Shelton RC, Othus MKD, Fontenot HB, Hanna R. Stage of adoption of the human papillomavirus vaccine among college women. Prev. Med. 45, 420-425 (2009).
74. Rosenthal SL, Weiss TW, Zimet GD, Ma L, Good MB, Vichnin MD. Predictors of HPV vaccine among women aged 19-26: importance of a physicians recommendation. Vaccine DOI: 1010.6/j. vaccine.2009.12.063 (2009) (Epub ahead of print).
75. Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey - Adult 2007. Prev. Med. 48, 426-431 (2009).
76. Licht AS, Murphy JM, Hyland AJ, Fix BV, Hawk LW, Mahoney MC. Is use of the human papillomavirus vaccine among female college students related to human papillomavirus knowledge and risk perception? Sex. Trans. Infect. 86, 74-78 (2010).
77. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex. Trans. Infect. 85, 499-502 (2009).
78. Harper DM. Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global health. Pub. Health Gen. 12, 319-330 (2009).
79. Kim JJ, Ortendahl J, Goldie SJ. Cost- effectiveness of human papillomavirus vaccination and cervical cancer screening in women older that 30 in the United States. Ann. Int. Med. 151, 538-555 (2009).
80. Kjaer SK, Sigurdsson K, Iversen O-E et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev. Res. 10, 868-878 (2009).
81. Rodríguez AC, Sciffman M, Herrero R et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. Natl Can. Inst. 102, 1-10 (2010).
82. Palefsky J, Giuliano A, on behalf of the male quadrivalent HPV vaccine efficacy trial study group. Efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related genital infection in young men. Presented at: The European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Conference. Nice, France, 13 November 2008.
83. Giuliano A, Palefsky J, on behalf of the male quadrivalent HPV vaccine efficacy trial study group. The efficacy of quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV infection and HPV-related genital disease in young men. Presented at: The European Research Organization on Genital Infection and Neoplasia (EUROGIN) International Multidisciplinary Conference. Nice, France, 13 November 2008.
84. Kim JJ, Goldie J. Cost-effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. Br. Med. J. 339, b3884 (2009).
85. Heck JE, Berthiller J, Vaccarella S et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium. Int. J. Epidemiol. 39, 166-181 (2010).
86. Reiter PL, Brewer NT, McRee A-L, Gilbert P, Smith JS. Acceptability of HPV vaccine among a national sample of gay and bisexual men. Sex. Trans. Dis. 37, 197-203 (2010).
87. Yee LJ, Rhodes SD. Understanding correlates of hepatitis B virus vaccination in men who have sex with men: what have we learned? Sex. Transm. Infect. 78, 374-377 (2002).
88. Reiter PL, Brewer NT, Smith JS. HPV knowledge and HPV vaccine acceptability among a national sample of heterosexual males. Sex. Transm. Infect. 86, 241-246 (2009).
89. Ferris DG, Waller JL, Miller J et al. Variables associated with human papillomavirus (HPV) vaccine acceptance by men. Am. Board Fam. Med. 22, 34-42 (2009).
90. Liddon N, Hood J, Wynn BA, Marlowitz LE. Acceptability of human papillomavirus vaccine for males: a review of the literature. J. Adolesc. Health 4, 113-123 (2010).
91. Gerend MA, Barley J. Human papillomavirus vaccine acceptability among young adult men. Sex. Trans. Dis. 36, 58-62 (2009).
92. Nielsen A, Munk C, Liaw K-L, Kjaer SK. Awareness of human papillomavirus in 23,000 Danish men from the general male population. J. Cancer Prev. 18, 236-239 (2009).
93. Ogilivie GS, Remple VP, Marra F et al. Intention of parents to have male children vaccinated with the human papillomavirus vaccine. Sex. Trans. Infect. 84, 318-323 (2008).
94. Jones M, Cook R. Intent to receive an HPV vaccination among university men and women and implications for vaccine administration. J. Am. Coll. Health 57, 23-32 (2008).
95. Lacey CJN, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11. Vaccine 24(Suppl. 3), 35-41 (2006).
96. Woodhall S, Jit M, Cai C et al. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex. Trans. Dis. 36, 515-521 (2009).
97. CDC. STD Treatment Guidelines 2006. MMWR 55, RR-11 (2006).
98. Mortenson GL, Larsen HK. The quality of life of patients with genital warts: a qualitative study. BMC Pub. Health 10, 113 (2010).
99. Waller J, Marlow LAV, Wardle J. Mothers attitudes towards preventing cervical cancer through human papillomavirus vaccination: a qualitative study. Cancer Epidemiol. Biomarkers Prev. 15, 1257-1261 (2006).
100. Mu?oz N, Kjaer SK, Sigursson K et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl Cancer Inst. 102, 325-329 (2010).
101. Neubrand TPL, Breitkopf CR, Rupp R, Breitkpf D, Rosenthal SL. Factors associated with completion of the human papillomavirus vaccine series. Clin. Peds. 48, 966-969 (2009).
102. Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine 28, 989-995 (2010).
103. Robbins SCC, Bernard D, McCaffery K, Brotherton J, Garland S, Skinner SR. Is cancer contagious?: Australian adolescent girls and their parents: making the most of limited information about HPV and HPV vaccination. Vaccine 28(19), 3398-3408 (2010).
104. Mathur MB, Mathur VS, Reichling DB. Participation in the decision to become vaccinated against human papillomavirus by California high school girls and the predictors of vaccine status. J. Ped. Health Care 24, 14-24 (2010).
105. ® vaccination status and knowledge amongst a nationally representative sample of Australian secondary students. Vaccine 28, 4416-4422 (2010).
106. Stretch R, Chambers G, Whittaker J et al. Implementing a school-based HPV vaccination programme. Nurs. Times 104, 30-33 (2008).
107. Stretch R, Roberts SA, McCann R et al. Parental attitudes and information needs in an adolescent HPV vaccination programme. Br. J. Cancer 99, 1908-1911 (2008).
108. Porta M. The improbable plunge - what facts refute reasons to expect that the effectiveness of HPV vaccine to prevent cervical cancer could be low? Prev. Med. 48, 407-410 (2009).
109. Howell-Jones R, Bailey A, Beddows S et al. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br. J. Cancer 103(2), 209-216 (2010).
110. Schiller JT, Day PM, Kines RC. Current understanding of the mechanism of HPV infection. Gynecol. Oncol. 118 (1 Suppl.), S12-S17 (2010).
111. Romanowski B, Schwarz T, Ferguson L et al. HPV-16/18 ASO4-adjuvanted vaccine administered as a 2-dose schedule compared with the standard 3-dose schedule. Presented at: The European Research Organization on Genital Infection and Neoplasia (EUROGIN). Monte Carlo, Monaco, 17-20 February 2009 (Abstract SS 11-15).
112. Zhang T, Xu Y, Qiao L, Wang Y et al. Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine 28, 3479-3487 (2010).
113. Jagu S, Karanam B, Gambhira R et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J. Natl Cancer Inst. 101, 782-792 (2009).
114. Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838-1847 (2009).
115. Karanam B, Gambhira R, Peng S et al. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine 27, 1040-1049 (2009).
116. ®. Summary of product characteristics. GSK, Uxbridge, UK (2009) http://emc.medicines.org.uk/ medicine/20204/SPC/ Cervarix/#PRODUCTINFO
117. ®. Summary of product characteristics. Merck, NJ, USA (2009) www.gardasil.com
118. ®. Vaccines and Related Biological Products Advisory Committee (VRBPAC) briefing document www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeeting/ BloodVaccinesanOtherBiologics/ VaccinesandRelatedBiolOgical ProductsAdvisoryCommittee/ UCM181371.pdf
119. European Cervical Cancer Association. HPV vaccination across Europe (2009) www.ecca.info/fileadmin/user-upload/ HPV-Vaccination/ECCA-HPV- Vaccination-April-2009.pdf
120. Department of Health. Information for Professionals (2010) www.immunisation.nhs.uk/Professional- Information
121. Department of Health and Health Protection Agency. Annual HPV vaccine uptake in England: 2008/09. Published January 2010. Electronic format only www.dh.gov.uk/publications
122. CDC. Vaccination coverage among US adults: national immunization survey-adult, 2007. Updated 2008 www.cdc.gov/vaccines/stats-surv/nis/ downloads/nis-adult-summer-2007.pdf.
123. Wong C. National HPV vaccine uptake and vaccination: predictors and barriers for girls 8-17 years old. United States, 2008. Abstract LBb. Presented at: National STD Prevention Conference. MN, USA, 10 March 2010 www.medscape.com/viewarticle/718413.
124. Broad spectrum HPV vaccine dose ranging study http://clinicaltrials.gov/ ct2/show/ NCT00260039